Health Research Center
Physiology, Endocrinology, MetabolismView Carol Everson, PhD Bio
Intervening in mild traumatic brain injury to improve outcomes. Our laboratory is investigating practical interventions that may be implemented in the field to improve outcomes after mild traumatic brain injury (mTBI). Each intervention under study – sleep augmentation, sleep restriction, caffeine, and sedation – is known to profoundly affect cerebral blood flow and metabolism, which are integral to injury sequelae. These interventions are being evaluated for changes to the extent and course of brain injury (i.e., local coherence of brain neural activity, functional brain connectivity, and microstructural disturbances) and for changes to hormonal and behavioral co-morbidities in mTBI. The results will provide basic proof of concept for practical and low-cost means to improve mTBI outcomes during acute and subacute postinjury intervals.
This initiative is supported by a grant awarded by the U.S. Army Medical Research & Development Command, Department of Defense. Collaborators include Drs. Brian Stemper and Matthew Budde, Department of Neurosurgery; Dr. Aniko Szabo, Institute for Health and Equity; and Dr. Thomas Hammeke (retired), Department of Psychiatry and Behavioral Medicine.
Deconstructing sleep disruption as a major risk factor for relapse in opioid use. The threat of relapse to opioid use is severe and unrelenting: 40-60% of individuals who misuse or become addicted to opioids relapse weeks or months after opioid withdrawal. Profound sleep disturbances during abstinence have long been suspected of perpetuating vulnerability to relapse. Our laboratory has shown that persistent sleep disruption dysregulates the hypothalamic-pituitary-adrenal (HPA) axis—a likely biological basis of vulnerability. Therefore, we are interrogating the HPA axis to isolate the mechanism that may be maintained in a dysregulated state by persistent sleep restriction during opioid abstinence. Furthermore, two clinically relevant approaches to situations where too little or too much HPA-axis output is suspected will be tested for treatment efficacy. The functional outcome measure will be the degree of mitigation of opioid drug seeking. Characterization of vulnerable phenotypes will include stress-induced changes glucocorticoids, pain sensitivity, and responses to novel environments which may predict vulnerability.
This is a multi-principal investigator project with Dr. Everson, Dr. Christopher Olsen, Department of Pharmacology & Toxicology and Dr. Hershel Raff, Departments of Medicine, Physiology and Surgery. Collaborating scientists include Dr. Aniko Szabo in the Institute for Health and Equity and Dr. Cheryl Stucky in the Department of Cell Biology, Neurobiology & Anatomy. This project is supported by a grant award from the National Institutes of Health HEAL (Helping to End Addiction Long-Term) Initiative.
Research Technologist II
Research Technologist I
(Swanson CM, Kohrt WM, Buxton OM, Everson CA, Wright KP Jr, Orwoll ES, Shea SA.) Metabolism. 2018 07;84:28-43 PMID: 29229227 PMCID: PMC5994176 SCOPUS ID: 2-s2.0-85040451185 12/13/2017
(Everson CA, Henchen CJ, Szabo A, Hogg N.) Sleep. 2014 Dec 01;37(12):1929-40 PMID: 25325492 PMCID: PMC4548518 SCOPUS ID: 2-s2.0-84914093940 10/18/2014
(Everson CA, Folley AE, Toth JM.) Exp Biol Med (Maywood). 2012 Sep;237(9):1101-9 PMID: 22946089 PMCID: PMC3939802 SCOPUS ID: 2-s2.0-84866443267 09/05/2012
(Everson CA, Szabo A.) PLoS One. 2011;6(8):e22987 PMID: 21853062 PMCID: PMC3154920 SCOPUS ID: 2-s2.0-80051644490 08/20/2011
(Everson CA, Szabo A.) Am J Physiol Regul Integr Comp Physiol. 2009 Nov;297(5):R1430-40 PMID: 19692662 PMCID: PMC2777777 SCOPUS ID: 2-s2.0-70449672782 08/21/2009
(Everson CA, Thalacker CD, Hogg N.) Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R2067-74 PMID: 18945949 PMCID: PMC2685300 SCOPUS ID: 2-s2.0-57749108208 10/24/2008
(Everson CA.) Am J Physiol Regul Integr Comp Physiol. 2005 Oct;289(4):R1054-63 PMID: 15947073 SCOPUS ID: 2-s2.0-25844438769 06/11/2005
(Everson CA, Laatsch CD, Hogg N.) Am J Physiol Regul Integr Comp Physiol. 2005 Feb;288(2):R374-83 PMID: 15472007 SCOPUS ID: 2-s2.0-12344316868 10/09/2004
(Everson CA, Crowley WR.) Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E1060-70 PMID: 14871886 SCOPUS ID: 2-s2.0-2442693138 02/12/2004
(Everson CA, Nowak TS Jr.) Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E85-93 PMID: 12067847 SCOPUS ID: 2-s2.0-0036298089 06/18/2002
(Rechtschaffen A, Bergmann BM.) Am J Physiol Regul Integr Comp Physiol. 2001 Feb;280(2):R602-3 PMID: 11270375 SCOPUS ID: 2-s2.0-0034999481 03/29/2001
(Everson CA, Toth LA.) Am J Physiol Regul Integr Comp Physiol. 2000 Apr;278(4):R905-16 PMID: 10749778 SCOPUS ID: 2-s2.0-0033994880 04/06/2000